Liraglutide
STEP 8
Novo Nordisk · Phase 3 · Completed · Enrollment 338
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Semaglutide | n/r | n/r | n/r | n/r |
| Placebo (semaglutide) | n/r | n/r | n/r | n/r |
| Liraglutide | n/r | n/r | n/r | n/r |
| Placebo (liraglutide) | n/r | n/r | n/r | n/r |
Not shown
- Semaglutide: endpoint not reported
- Placebo (semaglutide): endpoint not reported
- Liraglutide: endpoint not reported
- Placebo (liraglutide): endpoint not reported